Drug Profile
Research programme: GLP-1R/GIPR dual agonists - Carmot Therapeutics
Alternative Names: Inflammation therapeutics - Carmot Therapeutics; Neurodegenerative disease therapeutics - Carmot TherapeuticsLatest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Carmot Therapeutics
- Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Neuroprotectants; Obesity therapies; Peptides; Recombinant fusion proteins; Small molecules
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Discontinued Inflammation; Neurodegenerative disorders
Most Recent Events
- 29 Jan 2024 Carmot Therapeutics has been acquired by Roche
- 28 Feb 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Obesity in USA (PO)